Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.82 [1][6]. Core Insights - The company has successfully licensed its TL1A/IL-23p19 dual antibody SIM0709 to Boehringer Ingelheim for an upfront payment of €42 million and a total deal value of €1.058 billion, indicating strong validation of its innovative research and development capabilities [1]. - The company has seen recognition from major multinational corporations (MNCs) such as AbbVie, BI, and Ipsen for its innovative pipeline, with four projects launched overseas since 2025 [1]. - The global market for Inflammatory Bowel Disease (IBD) is projected to reach USD 28 billion by 2028, with the TL1A target showing significant potential for treatment [2]. - SIM0709 is designed as a long-acting dual antibody with a potential dosing interval of three months, which could position it favorably in the competitive landscape for IBD treatments [3]. - Boehringer Ingelheim's established global development capabilities are expected to significantly support the global expansion of SIM0709, as it is a key player in the autoimmune disease treatment space [4]. - The company is advancing its innovative platforms, including TCE and ADC, with ongoing clinical trials and collaborations that are expected to yield data within the year [5]. Financial Projections - The company forecasts adjusted net profits of RMB 1.18 billion, RMB 1.40 billion, and RMB 1.52 billion for the years 2025, 2026, and 2027 respectively, reflecting a compound annual growth rate (CAGR) of 14% [6][12]. - The earnings per share (EPS) estimates are projected at RMB 0.45, RMB 0.54, and RMB 0.59 for the years 2025, 2026, and 2027 respectively [6][12]. - The company maintains a price-to-earnings (PE) ratio of 33.19x for 2026, supporting the target price of HKD 19.82 [6][12].

Group 1: Macro Overview - The Federal Reserve maintained the policy interest rate at 3.5-3.75% during the January FOMC meeting, expressing a more optimistic outlook on the economy and job market [2] - The Hang Seng Index and Hang Seng Tech Index both rose over 2.5%, with the Hang Seng Index surpassing 27,800 points, marking a new high since 2021 [2] - The report suggests that the first quarter may be a critical period for the Hong Kong stock market, with potential for further growth driven by liquidity, capital, and earnings [2] Group 2: Utility and Environmental Sector - The carbon pricing market is expected to stabilize after a decline in 2025, with projections indicating a price of 150-200 RMB/ton by 2030 [4] - Companies in the green electricity and environmental sectors, such as Longyuan Power and China Everbright Environment, are expected to benefit from the rising carbon costs and green certificate revenues [4] - Potential catalysts for growth include the introduction of policies linking green certificates to carbon quotas and the expansion of the carbon market [4] Group 3: Key Companies - Disco Corporation is positioned to benefit from the new AI chip generation, with a target price of 79,000 JPY, reflecting a 48x FY26E PE [5] - Xiansheng Pharmaceutical has successfully licensed its dual antibody SIM0709 to Boehringer Ingelheim, validating its innovation system and maintaining a "buy" rating [6] - Industrial Fulian expects a significant increase in net profit for 2025, with projections of 35.1-35.7 billion RMB, driven by the launch of new products and vertical integration advantages [8] - Anta Sports is set to acquire a 29.06% stake in PUMA for approximately 1.506 billion euros, enhancing its global brand portfolio and market presence [8] - Jingwei Hengrun anticipates a turnaround in profitability for 2025, projecting a net profit of 0.75-1.1 billion RMB, supported by scale effects [11] - Ruya Chen expects continued high growth in its self-owned brand business, with a projected net profit of 176-200 million RMB for 2025 [12] - Wancheng Group is expected to improve same-store performance and maintain a rapid store opening pace, supported by supply chain efficiency [13] - Ugreen Technology is focusing on AI and NAS integration, with a projected net profit of 653-733 million RMB for 2025 [14]